1,4-二氨基(丁烷-d₈)二盐酸盐 | 284665-22-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1,4-二氨基(丁烷-d₈)二盐酸盐
• 英文名称: 1,4-Butane-d8-diamine 2hcl
• 英文别名: 1,1,2,2,3,3,4,4-octadeuteriobutane-1,4-diamine;dihydrochloride
• CAS: 284665-22-1
• 化学式: C4H14Cl2N2
• 分子量: 169.12
• InChiKey: XXWCODXIQWIHQN-VHGLFXLXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.53
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  4
• 氢受体数：
  2

文献信息

• Urinary polyamines as prostate cancer detection biomarkers
  申请人：New Life Medicine Technology Company Limited

  公开号：US10816478B2

  公开（公告）日：2020-10-27

  Luminescent lanthanide complexes comprising a triazine-based ligand capable of selective detection of urinary polyamines and their methods of use in detecting and quantifying urinary polyamines as well as prostate cancer biomarkers, such as spermine. The detection of the urinary polyamines can be accomplished using colorimetric methods such as, with an ultraviolet-visible spectrometer.

  发光镧系配合物，包含能够选择性检测尿多胺的三嗪基配体，及其用于检测和量化尿多胺和前列腺癌生物标志物（如精胺）的方法。尿多胺的检测可采用比色法，如紫外-可见光谱仪。
• URINARY POLYAMINES AS PROSTATE CANCER DETECTION BIOMARKERS
  申请人：New Life Medicine Technology Company Limited

  公开号：EP3526213B1

  公开（公告）日：2021-02-17
• Urinary Polyamines as Prostate Cancer Detection Biomarkers
  申请人：Hong Kong Baptist University

  公开号：US20180172695A1

  公开（公告）日：2018-06-21

  The present disclosure relates to urinary polyamines useful as prostate cancer biomarkers. In particular, the present disclosure provides a novel, highly-sensitive and specific, method for detecting and quantifying urinary polyamines using lanthanide complexes or citrate capped gold nanoparticles.
• METHODS RELATED TO THE DIAGNOSIS OF PROSTATE CANCER
  申请人：YatHing Biotechnology Company Limited

  公开号：US20210333280A1

  公开（公告）日：2021-10-28

  Disclosed herein are methods of determining the risk of developing prostate cancer in a subject or determining whether a subject suffers from prostate cancer, the method comprising measuring the level of one or more polyamines in a fluid sample obtained from the subject, measuring at a variable selected from the group consisting of age, prostate volume (PV), prostate-specific antigen (PSA), digital rectal examination (DRE), and combinations thereof. Also disclosed herein are methods of determining the risk of developing prostate cancer in a subject or determining whether a subject suffers from prostate cancer, the method comprising obtaining a score value based on previously disclosed variables to predict the likelihood of the subject developing or having prostate cancer.